This phase III study is evaluating how safe and effective targeted therapy (itolizumab) is, compared to a placebo, in people with acute graft versus host disease .
This trial is treating patients with acute graft versus host disease.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Eligible participants will be randomly allocated to either the Experimental Arm or Placebo Comparator Arm. In the Experimental Arm, participants will receive itolizumab administered by intravenous infusion every two weeks for a total of 7 doses. In the Placebo Comparator Arm, participants will receive a Placebo administered intravenous infusion every 2 weeks for a total of 7 doses.
Recruiting Hospitals Read More